The growing emphasis on advanced liver fibrosis treatments highlights a paradigm shift in addressing chronic liver diseases, ...

The therapy showed a ‘favourable’ safety profile both as a single agent and in combination with standard-of-care treatment.

With better risk stratification, clinicians may be able to optimize medical management of patients with chronic HBV who don’t ...

Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced positive topline results from two ...

Preliminary fourth-quarter and full-year 2024 Rezdiffra™ (resmetirom) net sales ranges of $100 million to $103 million and $177 million to $180 ...

Primary endpoints for the blinded portion of the study include assessments of the safety and tolerability of EFX during 52 weeks of treatment ... changes from baseline in non-invasive markers of liver ...

Study Finds Targeting Inflammation May Not Help Reduce Liver Fibrosis in MAFLD July 26 ... Early detection has the potential to transform treatment and outcomes in cancer care, especially for ...

PRNewswire/ -- (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today ...

What do Sidney Crosby, Chuck Noll, Rocky Bleier, Dave Parker, Franco Harris, Jerome Bettis, Troy Polamalu, Cameron Heyward and Mike Ditka have in common?